In an ASCO Daily News guest essay, Penn Medicine - Abramson Cancer Center's Dr. Ramy Sedhom, MD emphasized the promise of #telehealth and electronic patient-reported outcomes, which allow #PalliativeCare patients to report their symptoms and well-being remotely and in real time. spr.ly/6011WeEzJ

CanNOT overstate the life changing role of palliative care - but it continues to be underutilized. Thank you Laura Petrillo 🗽 for dispelling the myths and emphasizing the need of early intervention! #WCLC24

Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults by Ramy Sedhom, MD Bobby Green Julia Frydman #bcsm ascopost.com/issues/septemb…

Always good to see Fumiko Ladd Chino, MD, FASCO at the forefront a patient problem Hopefully, we will continue conversations around policies that may not make sense, improve transparency, and systematically study what needs to change Thank you Tom Murphy for your hard work, bringing this to

This👏is👏 why there’s #burnout in #medicine. Stop telling physicians to meditate more — no amount of mindfulness erases the moral injury from third parties denying patients their basic symptom management meds. 🔸Important read from Tom Murphy AP News w insights from Fumiko Ladd Chino, MD, FASCO

Our thoughts on "rehabbed to death" in oncology. Recommend 1) prognostic and functional assessment, 2) clear criteria for rehab progress, and 3) early identification of those unlikely to benefit from rehab. bit.ly/4dWS3oV

An The ASCO Post guest essay by Ramy Sedhom, MD, FASCO offers several “commonsense interventions’” to optimize #cancer care for older patients, including whole-patient assessment, proactive monitoring, dose adjustment, and #palliativecare. spr.ly/6017WUtBF

Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults, by Ramy Sedhom, MD; Bobby Green, MD; and Julia Frydman, MD, MS ascopost.com/issues/septemb… #oncology #gerionc Ramy Sedhom, MD, FASCO Penn Medicine Thyme Care

Don Sullivan,MD,MA,MCR JAMA GeriPal - A Geriatrics & Palliative Care Podcast PalliPulm #pallipulm Yes! Very exciting. Critical contextual & practical considerations: all first consults IN-PERSON, primarily MD/NP (not multi-PC team), research team ensured virtual access (not routinely done in practice), few non-White and rural pts. Check out our Adam Spangler CAPC

@JAMA published very exciting REACH-PC study jamanetwork.com/journals/jama/…. As we consider applying these data into clinical practice, critical to note: (1) all first consults IN-PERSON, (2) all were "early" (<12 wks of Dx), (3) primarily MD/NP (not full multi-PC team), (4) research

2. #LITESPARK005: Update, Ph III, #Belzutifan vs Everolimus in previously treated mRCC: - U.S. FDA approved in December 2023 - Improved PFS (HR: 0.75) but no OS! - AEs w/ Belzutifan: Anemia, fatigue, arthralgias, and LFT abnormalities 3/6

A positive trial for cancer cachexia - a very distressing symptom to patients and caregivers! Congrats to my bud Eric Roeland, MD, FASCO, FAAHPM for being an NEJM author

NEJM RCT phase II study of ponsegromab (anti-GDF-15) vs placebo with increased weight gain, improved appetite and symptoms, and improved physical activity without increased AEs in people living with advanced lung and GI cancers. New findings in a critical unmet need! ASCO

Tatiana Prowell, MD Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation OncoAlert NEJM ESMO - Eur. Oncology From Vail to now, Tatiana Prowell, MD has been a steadfast supporter, sponsor, advocate, and friend who leads with kindness. It takes a village and everyone needs a Tatiana as part of their crew #mentorship

Dear Discussants, it is possible to contextualize the results of a study - that didn’t even show any OS benefit- without saying “this should be the new SOC” . It’s not that hard. Try saying “while the PFS results are statistically significant, no improvement in clinical outcomes